Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | POLB | P06746 | 5/20 | 0.41 |
| ▸ | USP2 | O75604 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286999 | 0.81 | HSD17B10 (0.47) | ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10 | |
| SCHEMBL27432878 | 0.81 | HSD17B10 (0.47) | ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10 | |
| SCHEMBL210291 | 0.79 | HSD17B10 (0.50) | ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10 | |
| Hydrochloric Acid SCHEMBL10496189 | 0.79 | HSD17B10 (0.46) | ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10 | |
| SCHEMBL114334 | 0.77 | MAPT (0.44) | ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10 | |
| SCHEMBL31016330 | 0.75 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10 | |
| SCHEMBL8829451 | 0.74 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10 | |
| SCHEMBL8615319 | 0.74 | HSD17B10 (0.43) | ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10 | |
| SCHEMBL19770791 | 0.74 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10 | |
| SCHEMBL8613502 | 0.74 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2TSHRLMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1052774-A | — | — | None | — | — | JP | disclosed |
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-12-02 | — | — | US | disclosed |
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2021-09-21 | — | — | US | disclosed |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC. DBA THE GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2020-06-11 | — | — | US | disclosed |
| US-10596175-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2020-03-24 | — | — | US | disclosed |
| US-20190000852-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2019-01-03 | — | — | US | disclosed |
| US-20170333437-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-11-23 | — | — | US | disclosed |
| US-20170333437-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS INSTITUTE FOR FUNCTIONAL GENOMICS, INC., DBA GENOMICS INSTITUTE OF THE NOVARTIS RESEARCH FOUNDATION | 2017-11-23 | — | — | US | disclosed |
| US-9700559-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-07-11 | — | — | US | disclosed |
| US-9700559-B2 | Compounds and compositions for the treatment of parasitic diseases | NOVARTIS AG (CH) | 2017-07-11 | — | — | US | disclosed |
| US-8383644-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2413693-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TransTech Pharma, Inc (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110160198-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2010114824-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TRANSTECH PHARMA INC (US) | 2010-10-07 | — | — | WO | disclosed |
| US-5731335-A | NERVOUS SYSTEM DISORDERS; STROKE; ANTIISCHEMIC AGENTS; COGNITION ACTIVATORS | ASTRA AKTIEBOLAG (SE) | 1998-03-24 | — | — | US | disclosed |
| US-5607956-A | TREATMENT OF NEURODEGENERATIVE DISORDERS SUCH AS CEREBRAL ISCHEMIA, ALZHEIMER'S DISEASE | ASTRA AKTIEBOLAG (SE) | 1997-03-04 | — | — | US | disclosed |
| CN-1126994-A | Novel (1-heteroazolyl-1-heterocyclyl) alkane derivatives and their use as neuroprotective agents | ASTRA AB (SE) | 1996-07-17 | — | — | CN | disclosed |
| EP-0707584-A1 | NOVEL (1-HETEROAZOLYL-1-HETEROCYCLYL)ALKANE DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE AGENTS | Astra Aktiebolag (SE) | 1996-04-24 | — | — | EP | disclosed |
| WO-1995001979-A1 | NOVEL (1-HETEROAZOLYL-1-HETEROCYCLYL)ALKANE DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE AGENTS | ASTRA AKTIEBOLAG (SE) | 1995-01-19 | — | — | WO | disclosed |
| JP-S6452774-A | AMIDE DERIVATIVE, PRODUCTION THEREOF AND PLANT DISEASE CONTROLLING AGENT CONTAINING SAID DERIVATIVE AS ACTIVE INGREDIENT | SUMITOMO CHEMICAL CO | 1989-02-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160198-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLP1R, GIPR, GPR119 | ALDH1A1 1899/4885SMN1; SMN2 3375/4885TSHR 361/4885 |
| US-20190000852-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | ALDH1A1 866/4885SMN1; SMN2 705/4885TSHR 2780/4885 |
| US-11123348-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | ALDH1A1 866/4885SMN1; SMN2 705/4885TSHR 2780/4885 |
| US-10596175-B2 | Compounds and compositions for the treatment of parasitic diseases | TYR, TBCA, MAPT | ALDH1A1 866/4885SMN1; SMN2 705/4885TSHR 2780/4885 |
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | ALDH1A1 866/4885SMN1; SMN2 705/4885TSHR 2780/4885 |
| US-20170333437-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | ALDH1A1 866/4885SMN1; SMN2 705/4885TSHR 2780/4885 |
| US-20200179391-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | ALDH1A1 866/4885SMN1; SMN2 705/4885TSHR 2780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.